All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
EC approves isatuximab combined with carfilzomib and dexamethasone for the treatment of relapsed MM
By Sumayya Khan
Bookmark this article
On April 19, 2021, it was announced that the European Commission (EC) approved the use of isatuximab (Isa) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma (MM) who have had ≥1 prior therapy. This approval was based on the results of the phase III IKEMA trial (NCT03275285), which were previously reported on the Multiple Myeloma Hub. They showed a 47% reduction in the risk of disease progression or death with Isa-Kd compared with Kd alone (HR, 0.531; 99% CI, 0.318–0.889; p = 0.0007).1
This Isa-Kd combination recently received approval from the U.S. Food and Drug Administration (FDA) for a similar indication, given on March 31, 2021.
- Sanofi.European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma. https://www.sanofi.com/en/media-room/press-releases/2021/2021-04-19-07-00-00-2212005. Published Apr 19, 2021. Accessed Apr 19, 2021.
Your opinion matters
0 votes - 88 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox